Astellas Announces Data from ASPIRO Study for AT132 (resamirigene bilparvovec) in X-linked Myotubular Myopathy Published in The Lancet Neurology

TOKYO, Nov. 15, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, " Astellas " ) today announced that The Lancet Neurology published a preliminary data analysis from the ASPIRO trial, evaluating...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials